KYTX (Kyverna Therapeutics) Marketable Securities: $204.25 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KYTX Kyverna Therapeutics Inc KYTX
12 GF Score
Price $7.42
! 1 Warning Sign
View Full Analysis

What is Kyverna Therapeutics Marketable Securities?

Kyverna Therapeutics KYTX +1.65% 12 Marketable Securities is $204.25 Mil as of Mar. 2026. GuruFocus rates KYTX with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Kyverna Therapeutics's Marketable Securities for the quarter that ended in Mar. 2026 was $204.25 Mil.

Kyverna Therapeutics's annual Marketable Securities increased from Dec. 2023 ($22.90 Mil) to Dec. 2024 ($189.36 Mil) but then declined from Dec. 2024 ($189.36 Mil) to Dec. 2025 ($155.16 Mil).

Kyverna Therapeutics  (NAS:KYTX) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Kyverna Therapeutics Marketable Securities Related Terms

Kyverna Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Kyverna Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyverna Therapeutics Marketable Securities Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
0.00 13.59 22.90 189.36 155.16

Kyverna Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 185.78 158.24 136.97 155.16 204.25
KYTX
12GF Score
Kyverna Therapeutics Inc KYTX
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyverna Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $204.25 Mil mean?
Kyverna Therapeutics (KYTX) has a Marketable Securities of $204.25 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Kyverna Therapeutics and its competitors.
Is Kyverna Therapeutics' Marketable Securities too high?
Kyverna Therapeutics' current Marketable Securities is $204.25 Mil. Overall, Kyverna Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kyverna Therapeutics' Marketable Securities compare to ZURA and CBIO?
Kyverna Therapeutics' Marketable Securities of $204.25 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Kyverna Therapeutics and its competitors. Kyverna Therapeutics's current Marketable Securities is $204.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyverna Therapeutics stock overvalued right now?
Kyverna Therapeutics (KYTX) has a current Marketable Securities of $204.25 Mil. The current Marketable Securities is $204.25 Mil. Kyverna Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Kyverna Therapeutics (KYTX), the current Marketable Securities is $204.25 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kyverna Therapeutics Business Description

Address 5980 Horton Street, Suite 550, Emeryville, CA, USA, 94608
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
12GF Score

Get the complete analysis for KYTX

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.42
Price